Joie Sun
Research Subjects
Joie Sun has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Pandey
Mass General Brigham 1 Division of Hematology/Oncology Harvard Medical School, Boston, Massachusetts
12 shared publications - Aparna Raj Parikh
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
12 shared publications - Ben Ouyang
Massachusetts General Hospital 3 Mass General Brigham Cancer Center Boston, Massachusetts
12 shared publications - Bennett A. Caughey
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
12 shared publications - Bruce Giantonio
Mass General Brigham Cancer Research Institute, Harvard Medical School, Boston, Massachusetts
12 shared publications - Bryan L. Peacker
Harvard Medical School, Boston, Massachusetts, USA; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Dermatology Section, VA Boston Healthcare System, Jamaica Plain, Massachusetts, USA
12 shared publications
Latest Publications
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Kaplan–Meier curves for survival outcomes in patients with MSS/pMMR mCRC receiving ICI-based therapies, stratified by liver metastasis status at the time of ICI initiation. A, PFS: Patients without liver metastases had significantly higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median PFS was 2.1 months (95% CI, 1.59–2.62) in those with liver metastases and 2.5 months (95% CI, 2.22–2.71) in those without liver metastases (HR, 1.68; 95% CI, 1.13–2.5; P = 0.009). B, OS: Median OS was 11.53 months (95% CI, 3.01–20.06) in those without liver metastases and 6.17 months (95% CI, 2.87–9.46) in those with liver metastases (HR, 2.03; 95% CI, 1.35–3.06; P < 0.001).
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Kaplan–Meier curves for survival outcomes in patients with MSS/pMMR mCRC receiving ICI-based therapies, stratified by liver metastasis status at the time of ICI initiation. A, PFS: Patients without liver metastases had significantly higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median PFS was 2.1 months (95% CI, 1.59–2.62) in those with liver metastases and 2.5 months (95% CI, 2.22–2.71) in those without liver metastases (HR, 1.68; 95% CI, 1.13–2.5; P = 0.009). B, OS: Median OS was 11.53 months (95% CI, 3.01–20.06) in those without liver metastases and 6.17 months (95% CI, 2.87–9.46) in those with liver metastases (HR, 2.03; 95% CI, 1.35–3.06; P < 0.001).
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Kaplan-Meier curves for survival outcomes in MSS/pMMR mCRC patients receiving ICI-based therapies, stratified by liver metastases status at baseline
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Kaplan-Meier curves for survival outcomes in MSS/pMMR mCRC patients receiving ICI-based therapies, stratified by liver metastases status at baseline
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Sites of progressive disease during immune checkpoint inhibitor-based therapy
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Sites of progressive disease during immune checkpoint inhibitor-based therapy
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Univariable and multivariable Cox regression analysis for PFS.
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Univariable and multivariable Cox regression analysis for PFS.
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICI) have limited efficacy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), potentially because of immunosuppressive mechanisms associated with liver metastases. The impact of liver metastases on survival outcomes was evaluated in a retrospective cohort of patients with MSS mCRC treated with ICI-based therapies at Mass General Brigham between January 2015 and December 2022. Patients were stratified by liver metastasis status at ICI initiation. The primary endpoint was progression-free survival (PFS); the secondary endpoint was overall survival (OS). A total of 132 patients were included, of whom 93 (70.5%) had liver metastases at ICI initiation. Most patients in both groups had received ≥2 prior lines of therapy. No significant differences were observed between groups for RAS/BRAF mutation status or tumor mutational burden. Patients without liver metastases demonstrated higher clinical benefit rates (46.2% vs. 16.1%; P = 0.001), longer median PFS (2.5 vs. 2.1 months; HR, 1.68; P = 0.009), and higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median OS was also prolonged in patients without liver metastases (11.5 vs. 6.2 months; HR, 2.03; P < 0.001). No history of liver metastases was an independent favorable risk factor for PFS and OS in univariable and multivariable analyses. These findings indicate that liver metastases are associated with inferior survival outcomes in patients with MSS mCRC treated with ICI-based therapies, supporting the immunosuppressive role of liver metastases and underscoring the importance of stratifying patients by liver metastasis status to guide patient selection and optimize therapeutic strategies.Significance:The limited efficacy of ICIs in MSS mCRC remains a major challenge. The association between liver metastases and inferior outcomes supports the liver’s immunosuppressive role and suggests that liver metastasis status may guide patient selection and treatment optimization.
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICI) have limited efficacy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), potentially because of immunosuppressive mechanisms associated with liver metastases. The impact of liver metastases on survival outcomes was evaluated in a retrospective cohort of patients with MSS mCRC treated with ICI-based therapies at Mass General Brigham between January 2015 and December 2022. Patients were stratified by liver metastasis status at ICI initiation. The primary endpoint was progression-free survival (PFS); the secondary endpoint was overall survival (OS). A total of 132 patients were included, of whom 93 (70.5%) had liver metastases at ICI initiation. Most patients in both groups had received ≥2 prior lines of therapy. No significant differences were observed between groups for RAS/BRAF mutation status or tumor mutational burden. Patients without liver metastases demonstrated higher clinical benefit rates (46.2% vs. 16.1%; P = 0.001), longer median PFS (2.5 vs. 2.1 months; HR, 1.68; P = 0.009), and higher 12-month PFS rates (12.8% vs. 1.1%; P = 0.034). The median OS was also prolonged in patients without liver metastases (11.5 vs. 6.2 months; HR, 2.03; P < 0.001). No history of liver metastases was an independent favorable risk factor for PFS and OS in univariable and multivariable analyses. These findings indicate that liver metastases are associated with inferior survival outcomes in patients with MSS mCRC treated with ICI-based therapies, supporting the immunosuppressive role of liver metastases and underscoring the importance of stratifying patients by liver metastasis status to guide patient selection and optimize therapeutic strategies.Significance:The limited efficacy of ICIs in MSS mCRC remains a major challenge. The association between liver metastases and inferior outcomes supports the liver’s immunosuppressive role and suggests that liver metastasis status may guide patient selection and treatment optimization.
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Univariable and multivariable Cox regression analysis for OS.
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Univariable and multivariable Cox regression analysis for OS.
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Details of molecular characteristics and tumor mutational burden by timing of treatment
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Details of molecular characteristics and tumor mutational burden by timing of treatment
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Demographic and clinical characteristics of patients with MSS/pMMR mCRC by liver metastasis status.
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Demographic and clinical characteristics of patients with MSS/pMMR mCRC by liver metastasis status.
- Open Access
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Subsequent treatments after immune checkpoint inhibitor-based therapy
- 18 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Subsequent treatments after immune checkpoint inhibitor-based therapy